Pith. sign in

REVIEW

Likelihood-based Modeling of Covariate-Specific Time-Dependent ROC Curves

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2502.20892 v2 pith:WA6JBTRU submitted 2025-02-28 stat.ME stat.AP

classification stat.MEstat.AP
keywords biomarkerprognosticcovariate-specificframeworktimetime-dependentaccuracybiomarkers
verification ladder T0 review T1 audit T2 compute T3 formal

Signed reviews

No signed human review yet.

0 comments
read the original abstract

Identifying reliable biomarkers for predicting clinical events in longitudinal studies is important for accurate disease prognosis and for guiding development of new treatments. However, prognostic studies are often observational, making it difficult to account for patient heterogeneity. In amyotrophic lateral sclerosis (ALS), factors such as age, site of onset and genetic status influence both survival and biomarker levels, yet their impact on the prognostic accuracy of biomarkers over time remains unclear. While time-dependent receiver operating characteristic methods have been developed to handle censored time-to-event outcomes, most do not adjust for covariates. To address this, we propose the nonparanormal prognostic biomarker framework, which models the joint distribution of the biomarker and event time while accounting for covariates. This allows estimation of covariate-specific time-dependent ROC curves and related summary measures. We apply the NPB framework to evaluate serum neurofilament light as a prognostic biomarker in ALS, showing that its accuracy varies over time and with patient characteristics. By capturing these covariate-specific effects, the NPB framework supports more targeted risk stratification and can potentially improve the design of clinical trials for new ALS treatments.

Discussion (0). Continue with ORCID to comment.

Pith tools